Glycomine Begins Patient Dosing In Phase 1 Study Of Glm101 For Treatment Of Pmm2-Cdg
Glycomine, Inc., A Biotechnology Company Focused On Developing New Therapies For Orphan Diseases, Announced That The Company Has Received Us Food And Drug Administration (Fda) Clearance Of An Investigational New Drug (Ind) Application For Glm101 For The Treatment Of Pmm2-Cdg And Has Initiated Dosing Healthy Volunteers In A Phase 1 Clinical Study. Glm101 Is A Mannose-1-Phosphate Replacement Therapy In Development To Treat Phosphomannomutase 2-Congenital Disorder Of Glycosylation (Pmm2-Cdg), Previously Known As Cdg Type Ia. Pmm2-Cdg Is The Most Prevalent Congenital Disease Of Glycosylation But Has No Fda-Approved Treatments.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
